PRISM Registry: Pseudobulbar Affect Registry Series

Avanir Pharmaceuticals

Status: Completed

Conditions: Traumatic Brain Injury; Alzheimer's Disease; Stroke; Parkinson's Disease; Amyotrophic Lateral Sclerosis (ALS); Multiple Sclerosis (MS)

Study type: Observational

Funder types: Industry

Identifiers

NCT01366027

11-AVR-REG-001

Details and patient eligibility

About

PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated.

The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including

• Alzheimer's disease
• Amyotrophic lateral sclerosis
• Multiple sclerosis
• Parkinson's disease
• Stroke
• Traumatic brain injury

Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.

Enrollment: 5,290 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• All participants must have underlying neurologic conditions known to be risk factors of PBA: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's Disease, Stroke, and Traumatic Brain Injury.
• The population for this study will be 18 years and over